Experts warn that oral weight-loss medications, easier to manufacture than injectables, could trigger a surge in counterfeit treatments. Eli Lilly's oral GLP-1 drug, Orforglipron, completed phase-three trials. The company submitted Orforglipron to the U.S. FDA for review.
Eli Lilly confirmed it is taking proactive measures to combat potential counterfeits. The company monitors online activity to remove fraudulent websites. Lilly shares information with authorities to protect the supply chain and ensure patient safety.